An interventional study of Antibiotic prescribing according to guidelines in Angina, Acute Bronchiolitis and Acute Bronchitis, sponsored by University Hospital, Caen. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Health services research
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.
We are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.
The study will include six primary care practices (24 physicians), with three practices in each study arm.
The aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a "viral infection prescription" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.
453 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.
This study's planned enrollment of 4,500 is above the median of 100 across 273 interventional studies indexed under Angina Pectoris.
Browse Angina Pectoris studies →University Hospital, Caen is the lead sponsor of 512 studies on the registry; 82 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis / Nasopharyngitis, Acute sinusitis)
Exclusion Criteria:
- Patient under legal protection
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary care practices in the control group do not receive any intervention and continue patient management according to their usual practices.
For the intervention group, two planned interventions will be planed and applied to the primary care practices: 1. Use of the OPIV (Viral Infection Prescription Tool). 2. A multidisciplinary collaboration protocol between general practitioners and pharmacists to evaluate antibiotic treatment durations. This intervention aims to strengthen collaborative practices. If a prescribed duration does not comply with recommendations, the pharmacist will discuss it with the prescriber, and the duration will be adjusted accordingly."
Other: Antibiotic prescribing according to guidelines
If necessary, the general practitioner prescribes antibiotics to patients consulting for an upper or lower respiratory tract infection, according to the guidelines.
Number of antibiotic treatment days prescribed for upper and lower respiratory tract infections.
The primary outcome of the study will be the number of antibiotic treatment days prescribed for upper and lower respiratory tract infections. This outcome is a composite measure reflecting the impact of both interventions. Antibiotic duration will be assessed by running a query in the electronic medical record system of the participating primary care practices. The primary outcome will be evaluated at the baseline.
Time frame: The primary outcome is measured at the time of prescription (i.e. at the baseline)
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.